L 709049

a reversible interleukin-1beta-converting enzyme inhibitor

Also Known As:

Ac-Tyr-Val-Ala-Asp-CHO; Ac-YVAD-cho; L 709,049; L-709,049; L-709049; N-acetyltyrosyl-valyl-alanyl-aspartyl aldehyde; YCAD-CHO; acetyl-Tyr-Val-Ala-Asp-CHO; acetyl-tyrosyl-valyl-alanyl-aspartinal

Networked: 7 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - L 709049: 7

Experts

1.	Chen, Rongchang: 1 article (01/2019)
2.	Chen, Shuyu: 1 article (01/2019)
3.	Guan, Hongbing: 1 article (01/2019)
4.	He, Qiaoling: 1 article (01/2019)
5.	Huang, Peikai: 1 article (01/2019)
6.	Luo, Yiqin: 1 article (01/2019)
7.	Peng, Guoyou: 1 article (01/2019)
8.	Tao, Ailin: 1 article (01/2019)
9.	Wei, Shushan: 1 article (01/2019)
10.	Yan, Jie: 1 article (01/2019)

Related Diseases

1.	Reperfusion Injury 10/01/1999 - "To study the roles of the caspases in retinal ischemia-reperfusion injury, an inhibitor of caspase-1, acetyl-tyrosyl-valyl-alanyl-aspart-1-al (Ac-YVAD-CHO; total dose, 10(-7) moles) and that of caspase-3, acetyl-aspartyl-glutamylvalyl-aspart-1-al (Ac-DEVD-CHO; total dose, 10(-7) moles) was injected intravitreally and the number of TUNEL-positive cells was compared with the number in sections not treated with the inhibitors. "
2.	Inflammation (Inflammations) 05/01/2023 - "Interestingly, loss of ERα in HR+ cell lines is not responsive to tamoxifen, but highly sensitive to the inflammation inhibitor, Ac-YVAD-CHO. " 05/01/2023 - "To check tumor cell proliferation and migration of ERα KO breast cancer cell line, we used tamoxifen and the inflammation inhibitor Ac-YVAD-CHO. " 01/01/2019 - "Both VX-765 and Ac-YVAD-CHO effectively inhibited the activation of caspase-1 in TDI-asthmatic mice that was accompanied by dramatic attenuation of AHR, airway inflammation, and airway remodeling, in addition to a decreased TH2 response and lower levels of IL-18 and IL-1β. "
3.	Asthma (Bronchial Asthma) 01/01/2019 - "Using an established murine model of TDI-induced asthma as described previously, we gave the asthmatic mice a highly selective NLRP3 inhibitor, MCC950, as well as the specific caspase-1 inhibitors VX-765 and Ac-YVAD-CHO for therapeutic purposes. " 01/01/2017 - "The roles and potential for targeting of NLRP3 inflammasome, caspase-1, and IL-1β responses in experimental severe, steroid-resistant asthma were examined using a highly selective NLRP3 inhibitor, MCC950; the specific caspase-1 inhibitor Ac-YVAD-cho; and neutralizing anti-IL-1β antibody. "
4.	Airway Remodeling 01/01/2019 - "Both VX-765 and Ac-YVAD-CHO effectively inhibited the activation of caspase-1 in TDI-asthmatic mice that was accompanied by dramatic attenuation of AHR, airway inflammation, and airway remodeling, in addition to a decreased TH2 response and lower levels of IL-18 and IL-1β. "
5.	Neoplasms (Cancer) 05/01/2023 - "To check tumor cell proliferation and migration of ERα KO breast cancer cell line, we used tamoxifen and the inflammation inhibitor Ac-YVAD-CHO. "

Related Drugs and Biologics

1.	Caspase 3 (Caspase-3)
2.	acetyl-aspartyl-glutamyl-valyl-aspartal
3.	Caspases
4.	Retinaldehyde (Retinal)
5.	N- (1,2,3,5,6,7- hexahydro- S- indacen- 4- ylcarbamoyl)- 4- (2- hydroxy- 2- propanyl)- 2- furansulfonamide
6.	Inflammasomes
7.	Interleukin-18 (Interleukin 18)
8.	Tamoxifen
9.	Steroids
10.	Peptides (Polypeptides)